Cargando…
Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
CYP3A5 is the primary CYP3A subfamily enzyme expressed in the human kidney and its aberrant expression may contribute to a broad spectrum of renal disorders. Pharmacogenetic studies have reported inconsistent linkages between CYP3A5 expression and hypertension, however, most investigators have consi...
Autores principales: | Lidberg, Kevin A., Annalora, Andrew J., Jozic, Marija, Elson, Daniel J., Wang, Lu, Bammler, Theo K., Ramm, Susanne, Monteiro, Maria Beatriz, Himmelfarb, Jonathan, Marcus, Craig B., Iversen, Patrick L., Kelly, Edward J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907328/ https://www.ncbi.nlm.nih.gov/pubmed/33633318 http://dx.doi.org/10.1038/s41598-021-84194-w |
Ejemplares similares
-
Author Correction: Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
por: Lidberg, Kevin A., et al.
Publicado: (2021) -
A k-mer based transcriptomics approach for antisense drug discovery targeting the Ewing’s family of tumors
por: Annalora, Andrew J., et al.
Publicado: (2018) -
Induction of revertant fibres in the mdx mouse using antisense oligonucleotides
por: Fall, Abbie M, et al.
Publicado: (2006) -
Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020) -
Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)